X4 Pharmaceuticals, today highlighted data from a poster presentation of a clinical study with X4P-001-IO, an investigational CXCR4 allosteric antagonist, at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting, being held November 7-11, 2018, in Washington, D.C.
November 6, 2018
· 5 min read